This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Spectrum Pharma

When I asked Shrotriya about this, he told me that the Zevalin commercial launch is on track and that a replacement for Singh has already been hired. He added that Singh, despite the title of chief commercial officer, was more involved with new business development deals than he was in overseeing the Zevalin sales team. As CMO, Sandler was an important link between the company and physicians when it came to discussing Zevalin clinical data. He has not yet been replaced.

Spectrum chose not to disclose the departures of Sandler and Singh to investors because neither was considered a "key executive" per SEC rules, which would have required disclosure, says Shrotriya.

That might be a perfectly defensible argument from a legal perspective, but if I were an investor in Spectrum, I'd want to know that two top guys decided to find work elsewhere.

If Spectrum puts up solid Zevalin sales numbers in the second quarter and beyond, investors won't worry about the exit of Sandler and Singh. Until then, it's an overhang.
More on Biotech
13 Drugs Facing FDA Approval Decisions

Joel K. emails, "Thanks for your insight. I use to be a doubter of your columns but after getting burned multiple times by going contrarian, I have started listening and stopped losing. I would like to hear your thoughts on Vivus (VVUS - Get Report) and whether it is a good speculative play. I was impressed with the phase 3 erectile dysfunction drug data that was just released and I think the obesity drug has a good shot of approval."

I'm on record ranking the three obesity drug stocks in this order: 1) Vivus, 2) Arena Pharmaceuticals (ARNA - Get Report) and 3) Orexigen Therapeutics (OREX). My view seems to be in line with the market. Vivus is outperforming its weight-loss peers so far this year, even with the stock at $!0.60 down from its 52-week high of $13.68 reached last month.

I do worry that Vivus' run is done, or slowing down, now that we're less than a month away from the FDA advisory panel on July 15 which will review the company's weight-loss drug Qnexa. A positive recommendation from the FDA panel is no sure thing. Qnexa does a good job in helping obese patients lose weight, but the safety and tolerability of the two-drug regimen is a question mark.
2 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
APPY $2.91 0.70%
ARNA $1.56 -1.30%
DNDN $0.06 -6.02%
DSCO $2.17 -5.83%
SPPI $6.44 -7.50%


Chart of I:DJI
DOW 17,641.98 -9.28 -0.05%
S&P 500 2,049.49 -1.63 -0.08%
NASDAQ 4,721.0070 -4.6320 -0.10%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs